Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial
- 1 May 2010
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 118 (1-3) , 218-223
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of SchizophreniaAmerican Journal of Psychiatry, 2009
- Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trialJournal of Psychopharmacology, 2008
- Topiramate, nutrition and weight change: a prospective studyJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Is Acetazolamide Similar to Topiramate for Reversal of Antipsychotic-Induced Weight Gain?American Journal of Therapeutics, 2007
- Treatment with Olanzapine, Risperidone or Typical Antipsychotic Drugs in Asian Patients with SchizophreniaAustralian & New Zealand Journal of Psychiatry, 2006
- A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophreniaSchizophrenia Research, 2006
- Management of atypical antipsychotic‐induced weight gain in schizophrenic patients with topiramatePsychiatry and Clinical Neurosciences, 2005
- Topiramate Add-On in Treatment-Resistant SchizophreniaThe Journal of Clinical Psychiatry, 2005
- Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode PsychosisAmerican Journal of Psychiatry, 2005
- Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical AntipsychoticsAmerican Journal of Psychiatry, 2003